Compare DexCom, Inc. (DXCM) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Mattel Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while Mattel Inc trades at $16.7 (market cap $4.68B). The key difference: DexCom, Inc. is far larger — about 6.8× Mattel Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Mattel Inc for 97 Days on average.
| DXCM | MAT | |
|---|---|---|
Market Cap | $31.81B | $4.68B |
Volume | 2,861,821 | 11,617,958 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $22.16 |
52-Week Low | $54.84 | $12.66 |
Typical Hold Time | 62 Days | 97 Days |
Enterprise Value | $31.26B | $6.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Mattel (MAT) trades at $16.58, up 4.08% on takeover speculation from Authentic Brands Group, with technical indicators showing bullish momentum despite overbought RSI levels. The company maintains solid fundamentals with $5.35B revenue, 7.78% net margin, and attractive valuation at 12.22 P/E ratio. Recent CEO transition to Roger Lynch and potential acquisition interest create significant near-term catalysts.
The stock presents upside potential given the $18 high price target and bullish analyst consensus (53% buy ratings), though execution risks under new leadership and mixed earnings history warrant caution. The takeover premium provides support, but investors should monitor Q3 earnings delivery against the 0.974 EPS expectation for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
